Patients with high-grade alectinib-induced skin rash: How do we desensitize these patients? A case report and review of literature
With the advent of targeted therapy for non-small-cell lung cancer, there are many new available treatment options for patients whose cancer harbors an actionable mutation or alteration. These new medications come with numerous side effects, for some of which, the management is not well defined. Ale...
Main Authors: | Karan Seegobin, Umair Majeed, Yanyan Lou, Yujie Zhao, Rami Manochakian |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-10-01
|
Series: | SAGE Open Medical Case Reports |
Online Access: | https://doi.org/10.1177/2050313X20966895 |
Similar Items
-
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
by: Umair Majeed, et al.
Published: (2021-07-01) -
A Desquamating Skin Rash in a Pediatric Patient
by: John Haggerty, et al.
Published: (2019-05-01) -
Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer
by: Tatsuo Kimura, et al.
Published: (2016-12-01) -
A red-orange rash in a patient with skin of color
by: Ista A. Egbeto, BS, et al.
Published: (2021-03-01) -
Skin rash: Disease or drug?
by: Shikhar Kumar, et al.
Published: (2020-01-01)